Aim: To share our experience after 28 cryoablation treatments for prostate cancer (PCa) with histopathology, clinical data and MRI as the follow-up methods. Methods: Clinical follow-up comprised prostate specific antigen (PSA)-measurements, PSA-density and quality-of-life-parameters. multi-parametric (mp)MRI pre- and post-cryoablation were retrospectively re-analyzed in 23 cases using Likert scores. Follow-up-histopathology was performed via MRI/ultrasound fusion-guided and/or systematic biopsy. Receiver operating characteristic curve analysis was performed. Results: 17 PCa (61%) were diagnosed within 12-month post-cryotherapy (infield and out-of-field disease). PSA levels and PSA density were not significantly different between patients with or without PCa recurrence. mpMRI can characterize the decrease in prostate volume and necrosis. Area under the curve for the detection of PCa was 81% (global Likert scores), 74-87% (T2), 78% (diffusion weighted imaging) and 57-78% (dynamic contrast enhanced imaging; Youden-selected cutoff ≥3). Conclusion: Besides histopathological evaluation and control biopsy, MRI might have the potential to accurately detect PCa after cryotherapy. Clinical data and interdisciplinary communication are required for efficient monitoring after cryoablation treatments for PCa.
Future oncology (London, England). 2022 Mar 08 [Epub ahead of print]
Inga Peters, Katja Derlin, Matti Joonas Peperhove, Bennet Hensen, Stefanie Pertschy, Mathias Wolters, Christoph-Alexander Joachim von Klot, Frank Wacker, Susanne Hellms
Department of Urology & Urologic Oncology, Hannover Medical School, Carl-Neuberg Str. 1, Hannover, 30625, Germany., Institute for Diagnostic & Interventional Radiology, Hannover Medical School, Carl-Neuberg Str. 1, Hannover, 30625, Germany.